Bibliometric Analysis of Publication Activity in the Field of GIANT Cell Arteritis: A SCOPUS-based Study.

Objective Giant cell arthritis (GCA) is a type of vasculitis which is more common in female gender and is closely associated with Polymyalgia rheumatic. One of its important complication include visual impairment. The burden of disease is expected to be very high by 2050 and there is a need to compile the data on most influential studies on GCA to define future strategy to deal with this dangerous disease. Bibliometrics is a statistical analysis of published literature that reflects the value and impact of a particular publication within the specific field. Aim of our study is identify the most significant contributors and their quality of contribution in the field. Method We conducted this analysis utilizing SCOPUS database using different related MeSH terms. After a detailed screening, the list of top-50 articles were presented in the results in descending order of their ranks on the basis of their total number of citation. Most of our data comprises of publications from 1971-2012. Result The top-50 most cited articles on GCA were published between 1971 and 2012 with the median number of citations 274 ranging from 598-187. Annals of Internal Medicine was the top ranked journal with 13 publications from the list. The highly ranked author based on the number of publications was Hunder GG (20 publications) with h-index of 40, retaining affiliation with Mayo Clinic, Rochester, United States. Mayo Clinic was the most frequently mentioned institute among the affiliations. The United States was found to be the most productive country rendering most of the articles (64%). Conclusion Our bibliometric analysis on Giant cell arteritis identifies the information which may direct future research contributions, identify field experts, guide researchers to fill knowledge gaps, and assist in research fund allocation.

Molecular docking of alpha-enolase to elucidate the promising candidates against Streptococcus pneumoniae infection.

PURPOSE: To predict potential inhibitors of alpha-enolase to reduce plasminogen binding of Streptococcus pneumoniae (S. pneumoniae) that may lead as an orally active drug. S. pneumoniae remains dominant in causing invasive diseases. Fibrinolytic pathway is a critical factor of S. pneumoniae to invade and progression of disease in the host body. Besides the low mass on the cell surface, alpha-enolase possesses significant plasminogen binding among all exposed proteins. METHODS: In-silico based drug designing approach was implemented for evaluating potential inhibitors against alpha-enolase based on their binding affinities, energy score and pharmacokinetics. Lipinski's rule of five (LRo5) and Egan's (Brain Or IntestinaL EstimateD) BOILED-Egg methods were executed to predict the best ligand for biological systems. RESULTS: Molecular docking analysis revealed, Sodium (1,5-dihydroxy-2-oxopyrrolidin-3-yl)-hydroxy-dioxidophosphanium (SF-2312) as a promising inhibitor that fabricates finest attractive charges and conventional hydrogen bonds with S. pneumoniae alpha-enolase. Moreover, the pharmacokinetics of SF-2312 predict it as a therapeutic inhibitor for clinical trials. Like SF-2312, phosphono-acetohydroxamate (PhAH) also constructed adequate interactions at the active site of alpha-enolase, but it predicted less favourable than SF-2312 based on binding affinity. CONCLUSION: Briefly, SF-2312 and PhAH ligands could inhibit the role of alpha-enolase to restrain plasminogen binding, invasion and progression of S. pneumoniae. As per our investigation and analysis, SF-2312 is the most potent naturally existing inhibitor of S. pneumoniae alpha-enolase in current time.

Acinetobacter Spp: Resistance and therapeutic decisions at the turn of the novel millennium.

This study was planned to evaluate sample wise isolation and antimicrobial resistant trends of Acinetobacter spp in different departments of a tertiary care hospital. This was a transversal descriptive study, carried out in the clinical microbiology laboratory of the Allama Iqbal Medical College/ Jinnah Hospital, Lahore, Pakistan, during the period of January 2015 to December 2016. Every clinical specimen was processed for bacterial culture and antimicrobial susceptibly testing. A total of 3590 (2015=1780, 2016=1810) clinical specimens were processed. Of the total, only 54.7% were gram-negative, among these Acinetobacter spp were isolated from 10.1% and 16.5% samples respectively in 2015-16 with an overall rate of 24.3%. The highest occurrence of Acinetobacter spp isolates was reported from Intensive care units (ICU) (54%) followed by surgical units (25%) and medical units (16%). It is noteworthy that ICU and internal medicine showed the highest resistance rates, whereas, lower resistance rate was observed for the outdoor patients (OPD). Although collistin showed 0% resistant while ceftriaxone, ciprofloxacin, gentamicin, and tigecycline showed 90%, 68%, 66%, 66% and 62% resistance against Acinetobacter spp. respectively. An alarming increase in the resistance rate of meropenem, cefoperazone/sulbactam, piperacillin/ tazobactam, ciprofloxacin, and imipenem was observed from the year 2015 to 2016. This startling resistance acquired by Acinetobacter spp. within a period of one year, represent very limited therapeutic options left for the infections caused by Acinetobacter spp. Unavailability of effective drugs and limited therapeutic options enforce the health care practitioners to prescribe expensive and broad range antibiotics, which may cause harm to the patient. Therefore, it is need of an hour to better understand the antimicrobial patterns and optimize antimicrobial prescription policies for the control of multidrug-resistant Acinetobacter spp.